Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03579836 | Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 75 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06867172 | Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma(SPACE) | recruiting | — | 66 | Carol Davila University of Medicine and PharmacyOTHER | 1 | Mar 10, 2025 |
| clinicaltrials |
| NCT06344156 | Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer | recruiting | Phase 1 | 43 | Sichuan UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT02674100 | American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | recruiting | — | 500 | University of LouisvilleOTHER | 6 | Feb 25, 2025 | clinicaltrials |
| NCT05245877 | Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery(PREPOSTEROUS2) | recruiting | Phase 4 | 800 | Helsinki University Central HospitalOTHER | 3 | Feb 14, 2025 | clinicaltrials |
| NCT06578052 | Irinotecan Liposome in Combination With Capecitabine | recruiting | N/A | 20 | Junjie HangOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04136132 | Prospective Monocentric Clinical-biological Database(BCBPancréas) | recruiting | N/A | 120 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06144762 | Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer(PANC-O-MICS) | recruiting | N/A | 150 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05737953 | Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples | recruiting | — | 100 | Zhaoshen LiOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06819215 | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 188 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06139042 | Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers | recruiting | — | 1,608 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06427447 | Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)(ADJUPANC) | recruiting | Phase 3 | 770 | Changhai HospitalOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06387342 | Namodenoson Treatment of Advanced Pancreatic Cancer | recruiting | Phase 2 | 20 | Can-Fite BioPharmaINDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06789679 | Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer | recruiting | Phase 2 | 128 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800469 | Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer | recruiting | N/A | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05841420 | Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer | recruiting | Phase 2 | 98 | Morten LadekarlOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06782685 | Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV | recruiting | Phase 1 / Phase 2 | 138 | Dai, GuanghaiOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06777030 | Role of Exosomes in Pancreatic Cancer Progression | recruiting | — | 60 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06572813 | Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer(CISPD-7) | recruiting | Phase 1 / Phase 2 | 63 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06592989 | A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET | recruiting | — | 20 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06764134 | Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler(AEON-DP) | recruiting | — | 110 | University Hospital HeidelbergOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06761027 | mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Provincial HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | recruiting | Phase 3 | 480 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05218889 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05501379 | Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker(OncoPhys) | recruiting | — | 60 | University Medicine GreifswaldOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06747481 | Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer | recruiting | — | 323 | University of Las Palmas de Gran CanariaOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05859750 | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 78 | AkesoINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06601010 | The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer. | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05606523 | Microbiota and Pancreatic Cancer Cachexia(EXTRA) | recruiting | — | 24 | Genton Graf LaurenceOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06148298 | Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer | recruiting | — | 24 | University of Central FloridaOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06711211 | Spanish Registry of Digestive Tumours RETUD(RETUD) | recruiting | — | 20,000 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05529940 | NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) | recruiting | Phase 3 | 609 | Seoul National University HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06598033 | Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06601283 | Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06389760 | Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | recruiting | Phase 2 | 57 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT05851534 | Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas(PROMISE-P) | recruiting | N/A | 2,575 | Maastricht University Medical CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06655233 | Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis. | recruiting | — | 50 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05744219 | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial(IRIS) | recruiting | Phase 3 | 338 | Jon UnossonOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05784311 | Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)(SPARROW) | recruiting | Phase 4 | 344 | Leiden University Medical CenterOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06041009 | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | recruiting | — | 2,100 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06649474 | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1(HEPATOXALI) | recruiting | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05462496 | Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04571294 | Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy(PALN) | recruiting | N/A | 180 | Humanitas Hospital, ItalyOTHER | 1 | Oct 4, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2025source: clinicaltrials